Skip to main content
Figure 1 | BMC Psychiatry

Figure 1

From: Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study

Figure 1

Flow of patients through the study. Not meeting inclusion criteria = a score below 4 on all items: Delusions, Hallucinatory Behavior, Grandiosity, Suspiciousness/Persecution, or Unusual thought content in the Positive and Negative Syndrome Scale (PANSS); Uncooperative = the patient was not able or willing to cooperate with testing and assessments; Organic brain dis. = Organic brain disorder, principally dementia; Randomization not acceptable = patient or treating clinician not willing to change existing antipsychotic medication; Administrative causes = principally the result of patient discharge before assessments could be made.1 Enrollment started in 2003, week 10 until 2008, week 26. Full details on enrollment were only registered from 2006, week 31 until 2008, week 26. Consequently only percentages are displayed for patients assessed for eligibility and excluded patients.2 Before discharge/6 weeks. 3 One patient in the risperidone and olanzapine groups missed the first follow-up visit, but was retested on later visits.

Back to article page